Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification - Summary - MDSpire
Advertisement
Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification
To investigate the associations between pretreatment NLR, PLR, and clinicopathological characteristics, and evaluate their significance in neuroblastoma risk stratification, highlighting their potential impact on treatment decisions.
Key Findings:
Optimal cutoff values for NLR and PLR were established at 0.98 and 104.6, respectively, indicating their potential utility in clinical settings.
The combined NLR-PLR model yielded an AUC of 0.833 for differentiating high-risk from low/intermediate-risk patients, suggesting a significant improvement in risk assessment.
Elevated baseline NLR and PLR values were significantly associated with advanced disease stages, underscoring their prognostic relevance.
Interpretation:
Pretreatment NLR and PLR are significant biomarkers correlating with high-risk neuroblastoma and poor prognostic indicators, suggesting avenues for future research.
Limitations:
Single-center study may limit generalizability.
Retrospective design may introduce selection bias.
Small sample size may affect the robustness of the findings.
Conclusion:
Incorporating NLR and PLR into standard staging protocols may enhance risk stratification precision, potentially influencing treatment decisions.
